Science

Science, technology and the emergence of AI have converged to make precision medicine for acute care a reality. This is how we deliver healthcare tailored to biology.

NOSIS™ Foundation Model

Partners

Evidence

Platform

Prenosis is developing a pipeline of integrated diagnostics and therapeutics grounded in each patient's unique biological profile, using deep data science and AI to give clinicians tools that reflect the true complexity of critical disease.

Sepsis ImmunoScore®

Clinical Trials

Pipeline

Resources

Blogs, articles, videos, and podcasts exploring how precision medicine and AI are changing the way clinicians detect and treat critical conditions.

Newsroom

Resource Library

Events

About

As a biology-based technology company, we combine data science with AI to transform how critical conditions are diagnosed and treated.

Mission, Vision & Values

Careers

Leadership

Investors

Awards

Contact

Science

Science, technology and the emergence of AI have converged to make precision medicine for acute care a reality. This is how we deliver healthcare tailored to biology.

NOSIS™ Foundation Model

Partners

Evidence

BioAegis Therapeutics Announces Collaboration with Prenosis to Advance AI-Driven Precision Medicine in Inflammatory Disease

Read More →

Platform

Prenosis is developing a pipeline of integrated diagnostics and therapeutics grounded in each patient's unique biological profile, using deep data science and AI to give clinicians tools that reflect the true complexity of critical disease.

Sepsis ImmunoScore®

Clinical Trials

Pipeline

The Sepsis ImmunoScore® Predicts Sepsis, Mortality, and Deterioration Better than Clinical Scores and Widely Available Biomarkers

Read More →

Resources

Blogs, articles, videos, and podcasts exploring how precision medicine and AI are changing the way clinicians detect and treat critical conditions.

Newsroom

Resource Library

Events

AI’s Next Life Sciences Frontier: The Drugs We Need May Already Exist

Read More →

Newsroom

Read the latest Prenosis peer-reviewed articles and items from scholarly journals.

Newsroom

Sepsis ImmunoScore Outperforms Conventional Sepsis Tools

Read More →

About

As a biology-based technology company, we combine data science with AI to transform how critical conditions are diagnosed and treated.

Mission, Vision & Values

Careers

Leadership

Investors

Awards

Prenosis and Carle Health Mark Sepsis ImmunoScore® Clinical Deployment and First Patients Enrolled in OBSERVE-ARDS Clinical Study

Read More →

FDA Approves AI Tool That Can Detect Sepsis–Forbes

Forbes, a global leader in business and innovation coverage, profiled Prenosis and its groundbreaking FDA-authorized Sepsis ImmunoScore™:

The U.S. Food and Drug Administration approved an AI tool that can diagnose sepsis, Prenosis, the company behind the software, announced Wednesday, the latest in a series of agency approvals for AI diagnostic tools.
uncaptioned

KEY FACTS

The Sepsis ImmunoScore uses 22 diagnostic and predictive parameters to calculate the risk of a patient developing sepsis within 24 hours, a criteria combination that has “never previously been available in a legally marketed device” for the condition, according to a press release.

Prenosis spokesperson Gary Poole told Forbes the criteria includes inflammatory biomarkers, vital measurements and demographic information, among others.

The tool, which is integrated into hospitals’ electronic medical records, was built using the Chicago-based startup’s Immunix platform, which is a dataset containing more than 100,000 blood samples from more than 25,000 patients.

The Sepsis ImmunoScore was approved through the agency’s De Novo pathway, the process the FDA uses for novel medical devices.

Poole said the company plans to sell the Sepsis ImmunoScore at hospitals across the nation, adding it plans to announce a “distribution partnership with a large diagnostic company next week.”

Read the Forbes article.